DK2861223T3 - Sammensætninger og metoder til transmukosal absorption - Google Patents

Sammensætninger og metoder til transmukosal absorption Download PDF

Info

Publication number
DK2861223T3
DK2861223T3 DK13804115.7T DK13804115T DK2861223T3 DK 2861223 T3 DK2861223 T3 DK 2861223T3 DK 13804115 T DK13804115 T DK 13804115T DK 2861223 T3 DK2861223 T3 DK 2861223T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
transmucosal absorption
transmucosal
absorption
Prior art date
Application number
DK13804115.7T
Other languages
Danish (da)
English (en)
Inventor
Harry Brittain
Giorgio Reiner
Seth Lederman
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Application granted granted Critical
Publication of DK2861223T3 publication Critical patent/DK2861223T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
DK13804115.7T 2012-06-15 2013-06-14 Sammensætninger og metoder til transmukosal absorption DK2861223T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261660593P 2012-06-15 2012-06-15
US201261667774P 2012-07-03 2012-07-03
US201261725402P 2012-11-12 2012-11-12
US201361792900P 2013-03-15 2013-03-15
PCT/US2013/046023 WO2013188847A1 (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Publications (1)

Publication Number Publication Date
DK2861223T3 true DK2861223T3 (da) 2022-11-07

Family

ID=49758769

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13804115.7T DK2861223T3 (da) 2012-06-15 2013-06-14 Sammensætninger og metoder til transmukosal absorption

Country Status (26)

Country Link
US (2) US20140171515A1 (enExample)
EP (1) EP2861223B1 (enExample)
JP (5) JP6259452B2 (enExample)
CN (2) CN104684550A (enExample)
AR (1) AR092330A1 (enExample)
AU (2) AU2013274003B2 (enExample)
BR (1) BR112014031394B1 (enExample)
CA (2) CA2876902C (enExample)
DK (1) DK2861223T3 (enExample)
ES (1) ES2929133T3 (enExample)
HR (1) HRP20221325T1 (enExample)
HU (1) HUE060175T2 (enExample)
IL (1) IL236268B (enExample)
LT (1) LT2861223T (enExample)
MX (2) MX2021005317A (enExample)
MY (1) MY194495A (enExample)
NZ (2) NZ631144A (enExample)
PL (1) PL2861223T3 (enExample)
PT (1) PT2861223T (enExample)
RS (1) RS63822B1 (enExample)
SG (2) SG10201605407TA (enExample)
SI (1) SI2861223T1 (enExample)
SM (1) SMT202200436T1 (enExample)
TW (3) TWI590820B (enExample)
WO (1) WO2013188847A1 (enExample)
ZA (1) ZA201500288B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2501234T (pt) 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
MY196014A (en) 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
SG10201902203VA (en) 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
MX386469B (es) * 2015-07-15 2025-03-18 Theranexus Uso de amitriptilina para el bloqueo de hemicanales en el cerebro y metodo para la potenciacion de este efecto in vivo.
US12337063B2 (en) * 2016-09-02 2025-06-24 University Of Sharjah Formulation for atropine sulfate rapidly-disintegrating sublingual tablets
JP2020526592A (ja) 2017-07-13 2020-08-31 トニックス ファーマシューティカルズ ホールディング コーポレーション シクロベンザプリン類似体及びアミトリプチレン類似体
CN107519142B (zh) * 2017-08-24 2021-02-26 正大制药(青岛)有限公司 一种盐酸环苯扎林舌下片及其制备方法
CN107496355B (zh) * 2017-08-24 2021-04-30 正大制药(青岛)有限公司 一种盐酸环苯扎林舌下喷雾剂及其制备方法
MX2020004105A (es) * 2017-12-08 2020-09-22 Hoffmann La Roche Formulacion farmaceutica.
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
CN108721240A (zh) * 2018-06-08 2018-11-02 华益药业科技(安徽)有限公司 一种25mg阿米替林薄膜包衣片处方和工艺规程
EP3840738A1 (en) 2018-08-20 2021-06-30 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder
US20220339124A1 (en) * 2019-09-30 2022-10-27 Cadila Healthcare Limited Intranasal pharmaceutical compositions of cyclobenzaprine
JP7780447B2 (ja) 2020-04-08 2025-12-04 トニックス ファーマシューティカルズ ホールディング コーポレイション 性機能障害のシクロベンザプリン処置
MX2023005899A (es) 2020-11-20 2023-08-16 TONIX Pharmaceuticals Holding Corp Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol.
MX2023006720A (es) 2020-12-07 2023-08-18 TONIX Pharmaceuticals Holding Corp Tratamiento con ciclobenzaprina para fibromialgia.
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
US20240415789A1 (en) 2021-10-06 2024-12-19 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
EP4543427A1 (en) 2022-06-21 2025-04-30 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)
JP2025067457A (ja) * 2023-10-13 2025-04-24 株式会社島津製作所 液体クロマトグラフにおけるコストパフォーマンスの算出方法、プログラム、および、解析装置
WO2025160302A1 (en) 2024-01-25 2025-07-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for acute stress reaction or acute stress disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
PT1077683E (pt) * 1998-05-14 2003-04-30 Alza Corp Terapia anti-depressiva
AR025111A1 (es) 1999-08-13 2002-11-06 Janus Pharmaceuticals Inc Metodos y composiciones para tratar trastornos de ansiedad generalizada
AR025110A1 (es) 1999-08-13 2002-11-06 Vela Pharmaceuticals Inc Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002094229A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
WO2004071491A1 (en) * 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP2009079060A (ja) * 2008-10-15 2009-04-16 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
US20100266682A1 (en) * 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
PT2501234T (pt) * 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
US20110319389A1 (en) * 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
MY196014A (en) * 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride

Also Published As

Publication number Publication date
JP2024032964A (ja) 2024-03-12
JP2019123757A (ja) 2019-07-25
SG10201605407TA (en) 2016-08-30
WO2013188847A1 (en) 2013-12-19
HK1209361A1 (en) 2016-04-01
TW201731494A (zh) 2017-09-16
CA2876902C (en) 2021-07-13
CA3118913A1 (en) 2013-12-19
JP2015519404A (ja) 2015-07-09
BR112014031394B1 (pt) 2022-10-18
EP2861223B1 (en) 2022-08-03
US20140171515A1 (en) 2014-06-19
JP2017222726A (ja) 2017-12-21
RS63822B1 (sr) 2023-01-31
IL236268B (en) 2022-03-01
TW201408281A (zh) 2014-03-01
CN104684550A (zh) 2015-06-03
TW201842903A (zh) 2018-12-16
TWI683660B (zh) 2020-02-01
JP6259452B2 (ja) 2018-01-10
BR112014031394A8 (pt) 2021-11-03
CA2876902A1 (en) 2013-12-19
AR092330A1 (es) 2015-04-15
MY194495A (en) 2022-11-30
EP2861223A1 (en) 2015-04-22
MX2014015436A (es) 2015-07-14
PT2861223T (pt) 2022-11-07
US20260232578A1 (en) 2026-08-13
AU2013274003A1 (en) 2015-02-05
NZ631144A (en) 2016-12-23
AU2018241128B2 (en) 2020-05-21
SMT202200436T1 (it) 2023-01-13
HUE060175T2 (hu) 2023-02-28
JP2021138765A (ja) 2021-09-16
TWI590820B (zh) 2017-07-11
TWI642429B (zh) 2018-12-01
SI2861223T1 (sl) 2023-01-31
MX382516B (es) 2025-03-13
NZ726488A (en) 2018-10-26
ZA201500288B (en) 2022-05-25
WO2013188847A8 (en) 2015-02-05
LT2861223T (lt) 2022-12-12
MX2021005317A (es) 2022-12-16
AU2013274003B2 (en) 2018-07-05
IL236268A0 (en) 2015-02-26
EP2861223A4 (en) 2016-01-27
CA3118913C (en) 2024-04-30
CN111388430A (zh) 2020-07-10
AU2018241128A1 (en) 2018-10-25
HRP20221325T1 (hr) 2022-12-23
ES2929133T3 (es) 2022-11-25
SG11201408318RA (en) 2015-01-29
BR112014031394A2 (pt) 2017-06-27
PL2861223T3 (pl) 2022-12-12

Similar Documents

Publication Publication Date Title
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK2884999T3 (da) Fremgangsmåde og sammensætninger til cellulær immunterapi
ZA201500288B (en) Compositions and methods for transmucosal absorption
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2857401T3 (da) Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme
GB2499921B (en) Biophotonic compositions, kits and methods
DK2920167T3 (da) Hydrazinyl-indol-forbindelser og konjugater
DK3578201T3 (da) Fremgangsmåder og sammensætninger til naturlige dræberceller
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2906684T3 (da) T-celle-modificerende forbindelser og anvendelser deraf
BR112015003354A8 (pt) métodos e composições de microcápsula
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
EP2823306A4 (en) BIOMARKER COMPOSITIONS AND METHODS
BR112014032798A2 (pt) composição
DK2928921T3 (da) Sammensætninger og fremgangsmåder til antistoffer målrettet epo
DE102012104039A8 (de) Hubtoranordnung sowie Torsturz-Abdichteinrichtung hierfür
DK2830654T3 (da) Metoder og sammensætninger til behandling af inflammation
DK3930322T3 (da) Fremgangsmåder og anordninger til kodning
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
ME03413B (me) Kompozicije које sadrže peg i askorbat
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK2908661T3 (da) Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf
DK2896694T3 (da) Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3175852T3 (da) Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande